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Abstract: Obstructive sleep apnea (OSA) is a highly signiﬁ  cant condition based both on the 
high prevalence in community and signiﬁ  cant consequences. Obstructive sleep apnea syndrome 
(OSAS), OSA together with hypersomnolence, is seen in 4% of middle-aged men and 2% of 
middle-aged women. OSA is associated with impaired quality of life and increased risks of motor 
vehicle accidents, cardiovascular disease (including hypertension and coronary artery disease), 
and metabolic syndrome. There is some evidence for the use of conservative interventions such as 
weight loss and position modiﬁ  cation. CPAP remains the mainstay of treatment in this condition 
with high-level evidence supporting its efﬁ  cacy. Continuous positive airway pressure (CPAP) is 
an intrusive therapy, with long-term adherence rates of less than 70%. Dental appliances have 
been shown to be effective therapy in some subjects but are limited by the inability to predict 
treatment responders. Alternative treatments are discussed but there is little role for upper 
airway surgery (except in a select few experienced institutions) or pharmacological treatment. 
The current levels of evidence for the different treatment regimens are reviewed.
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Introduction
Obstructive sleep apnea (OSA) is a condition characterized by repetitive upper airway 
obstruction during sleep, resulting in arousal from sleep, sleep fragmentation, and 
variable arterial oxygen desaturation (Figure 1). The condition occurs in up to 24% 
of men and 9% of women (Young et al 1993) and is increased in prevalence in 
males, increasing age and obesity. Obstructive sleep apnea syndrome (OSAS), the 
combination of respiratory disturbance during sleep and symptoms, particularly 
daytime hypersomnolence, occurs in 4% of men and 2% of women based on large 
population studies (Young et al 1993).
The upper airway obstruction (apneas) or narrowing (hypopneas) occurs in the 
muscular pharynx with airway narrowing occurring predominantly in the lateral 
dimension (Bijaoui et al 2002; Akan et al 2004). The pathophysiology of OSA is 
thought to involve the loss of compensatory pharyngeal muscle dilator activity during 
sleep in subjects with anatomically compromised pharyngeal airways. Subjects with 
OSA tend to have smaller airway dimensions (Bradley et al 1986; Isono et al 1997). 
Subjects with OSA compared with those without have been shown to have a lower-
set hyoid bone even after correction for obesity (Riha et al 2005a). Pharyngeal dilator 
muscle activity, best studied in the genioglossus and tensor palatini muscles, is 
increased in wakefulness in subjects with OSA (Mezzanotte et al 1992; Fogel et al 
2001) but this compensatory augmented activity is lost at sleep onset (Mezzanotte et al 
1996; Fogel et al 2003, 2005) leading to upper airway obstruction during sleep. 
The control of dilator muscle activity is complex and may demonstrate phasic activity 
(increased activation during inspiration) or tonic activity (similar activation throughout 
inspiration and expiration) or both. Both phasic and tonic genioglossus activity is 
increased in subjects with OSA (Fogel et al 2001) and is dependent upon both local 
mechanisms, most likely as a reﬂ  ex response to negative airway pressure (Malhotra Neuropsychiatric Disease and Treatment 2006:2(3) 310
Hukins
et al 2000; Fogel et al 2001), and central activation by 
medullary respiratory neurons shortly before diaphragmatic 
activation (Horner 2000). There have been some recent 
insights into the neurochemical control of the upper airway 
dilator muscles. Most focus has been on serotonin, which 
exerts an excitatory effect on upper airway motor dilator 
neurons via serotonin receptor subtypes 2A and 2C in animal 
models (Fenik and Veasey 2003). Endogenous serotonin, 
however, appears to have minimal effect on genioglossus 
activity across sleep-wake states unless augmented by the 
upper airway reﬂ  ex inputs (Sood et al 2005).
Signiﬁ  cance of OSA
The cardinal symptoms of OSAS are sleepiness–fatigue or 
unrefreshing sleep as a consequence of the sleep fragmen-
tation due to upper airway obstruction during sleep. The 
correlation between the frequency of respiratory events or 
EEG arousals from sleep and reported sleepiness is not tight 
(Gonsalves et al 2004), indicating that other factors than 
sleep disturbance are involved, which may include sub-
cortical arousals, poor perception of sleepiness, differences 
in the biological susceptibility to sleep disturbance, and sleep 
habits. Chervin et al (2005) recently reported the presence 
of respiratory cycle related electro-encephalographic 
changes, brief changes to cortical activity that occur on a 
breath-by-breath basis in non-apneic sleep, in 38 adults 
evaluated by polysomnography. The variation in sigma EEG 
power within the respiratory cycle was most predictive 
of next day sleepiness, particularly in those subjects with 
underlying OSA. The authors speculated that the changes 
reﬂ  ected numerous inspiratory micro-arousals that may be 
involved in the pathogenesis of hypersomnolence.
The cost of OSA to the community includes both 
direct costs, such as cost of health care utilization, and 
indirect costs, such as the costs of impaired productivity, 
work-related accidents, motor-vehicle accidents and the 
health-care costs of diseases associated with OSA, particu-
larly cardiovascular disease. Case-controlled studies do show 
increased health-care utilization in patients with untreated 
OSA (Kryger et al 1996; Bahammam et al 1999; Kapur et al 
1999) and that health-care utilization progressively increases 
in the years before diagnosis and falls following effective 
treatment with continuous positive airway pressure (CPAP) 
(Albarrak et al 2005). Kapur et al (1999) estimated that the 
cost in 1999 of untreated moderate to severe OSA per year 
in the US was US$3.4 billion. Data from a large population 
study have shown than men with even mild OSA have a sig-
niﬁ  cantly increased risk for a motor vehicle accident but both 
men and women with at least moderate OSA have an odds 
ratio (OR) for multiple accidents of 7.3 (95% conﬁ  dence 
interval [CI] 2– 25) (Young et al 1997a). Several studies 
have reported increased mortality rates in subjects with 
untreated OSA but the methodology of these cohort studies is 
ﬂ  awed with potential for selection and lead-time bias (Lavie 
et al 1995; Marti et al 2002). Most of the deaths are related 
to cardiovascular disease.
Association with cardiovascular disease
The impact of OSA extends well beyond simply causing 
hypersomnolence. OSA has been known to be associated 
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Figure 1 Five-minute epoch of supine Stage II sleep in a subject with severe OSA. Cessation (apnea) in breathing (a) result in arterial oxygen desaturation (b) and EEG arousal 
from sleep (c). Chest wall motion continues during the apneas indicating that the events are due to upper airway obstruction.Neuropsychiatric Disease and Treatment 2006:2(3) 311
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with cardiovascular disease since the 1970s, including 
hypertension, myocardial infarction, and cerebrovascular 
disease, but it was not clear to what degree the relationship 
was cause and effect or related to confounding factors 
such as obesity, gender, and age. There have been several 
population-based epidemiological studies which now 
suggest a direct association between OSA and cardiovas-
cular disease.
A recent randomized, double-blind, placebo-controlled 
study suggests that OSA has direct effects on cardiac 
responses to exercise (Alonso-Fernandez et al 2006). 
Subjects with OSA have been shown to have reduced 
exercise-related increases in cardiac output and stroke 
volume compared with normal controls, despite normal 
resting left ventricular function. These depressed responses 
improve after 3 months of therapy with CPAP.
Hypertension
The Wisconsin Sleep Cohort Study is a prospective study 
of over 1100 subjects from a stratiﬁ  ed random cohort of 
employees from 4 Wisconsin state agencies. In the ﬁ  rst 
4–8 years of follow-up of 709 subjects, the study reported 
a corrected OR of 2.89 (95% CI 1.46–5.64) for the develop-
ment of hypertension (deﬁ  ned as a blood pressure of at least 
140/90 or the use of antihypertensive medications) in sub-
jects with an Apnea-Hypopnea Index (AHI, the number of 
apneas and hypopneas occurring per hour of sleep) of  15 
at baseline (normal  5,  15 indicating moderate OSA) 
compared with an AHI of zero at baseline (Peppard et al 
2000b). It was also surprising that the data demonstrated a 
dose response based on increasing AHI with an OR of 1.42 
(95% CI 1.13–1.78) for the development of hypertension 
in subjects with an AHI of 0.1–4.9 at baseline (that is still 
within the normal range for this measurement). The Sleep 
Heart Health Study also demonstrated a relationship between 
OSA and hypertension (also deﬁ  ned as a blood pressure of 
at least 140/90 or the use of antihypertensive medications) 
in cross-sectional analysis of 6132 subjects recruited from 
ongoing population studies. The OR (corrected for demo-
graphics, anthropometric variables, alcohol, and smoking) 
was 1.37 (95% CI 1.03–1.83) for the presence of hyper-
tension comparing the highest AHI quartile (AHI   30) 
to the lowest (AHI   1.5) (Nieto et al 2000). Data from 
the Wisconsin Sleep Cohort Study raises the possibility 
that there may be synergistic associations between OSA 
and angiotensin-converting enzyme (ACE) gene insertion/
deletion polysmorphisms and hypertension (Ling et al 
2004). In cross-sectional analysis of 1100 subjects, there 
was a strong association between subjects with mild to 
moderate OSA with ACE gene deletions and the presence 
of hypertension. The authors hypothesized that ACE gene 
deletion was only sufﬁ  cient to cause hypertension in the 
presence of sleep-disordered breathing but the effect of 
severe OSA on blood pressure overwhelms this association 
between gene deletion and hypertension.
Coronary artery disease
Numerous studies have demonstrated an increased prevalence 
of OSA at the time of diagnosis of coronary artery disease 
(Mooe et al 1996; Peker et al 1999) but these studies 
demonstrate the association between OSA and coronary 
artery disease at the point of time of a cardiac event rather 
than in the years leading up to the event when the coronary 
artery disease was developing. Many studies, including the 
larger population-based epidemiological studies, collate 
coronary artery disease with other cardiovascular outcomes 
as a composite outcome measure to achieve adequate 
statistical power (Shahar et al 2001). Longitudinal studies do 
suggest that OSA is a risk factor for coronary artery disease in 
both men and women. A 7-year prospective study of a sleep 
clinic cohort of 182 middle-aged men showed that untreated 
OSA was associated with the development of coronary artery 
disease, with an OR of 5.4 (95% CI 1.4–20.6) relative to 
non-OSA subjects (Peker et al 2002). In a prospective study 
of 103 women with repeated coronary angiography with 
an average interval of 3.25 years, the presence of snoring 
and tiredness was associated with larger progression of 
atherosclerosis after correction for other cardiac risk factors 
(Leineweber et al 2004).
Stroke
The association between stroke and OSA is complex. 
Self-reported snoring was associated with an increased 
risk of stroke in a large, prospective study with 8 years 
follow-up of 71  779 women, The Nurses Health Study 
(Hu et al 2000). The age-adjusted relative risk for stroke 
was 1.60 (95% CI 1.21–2.12) in occasional snorers 
and 1.88 (1.29–2.74) in regular snorers, although this 
relationship was no longer signiﬁ  cant after correction 
for other cardiovascular risk factors such as body mass 
index and smoking. Cross-sectional data from the Sleep 
Heart Health Study (6424 subjects) also failed to show a 
signiﬁ  cant association between OSA and the prevalence 
of stroke once corrected for all known cardiovascular risk 
factors (Shahar et al 2001). Cross-sectional data from the 
Wisconsin Sleep Cohort study (1475 subjects) did show Neuropsychiatric Disease and Treatment 2006:2(3) 312
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a signiﬁ  cant association after correction for confounding 
factors between at least moderate OSA (AHI of  20 events 
per sleep hour) and the prevalence of stroke with an OR of 
3.83 (95% CI 1.17–12.56) but no association with milder 
OSA (Artz et al 2005). However, 4-year longitudinal data 
from the same study did not demonstrate a signiﬁ  cant 
relationship between OSA and the incidence of stroke. 
OSA has been shown to be a risk factor for a composite 
end-point of stroke or death from any cause in a prospective 
observational cohort study of 1022 subjects referred to a 
sleep clinic (68% of which were subsequently diagnosed 
with OSA) with a reported hazard ratio for stroke or death 
from any cause of 1.97 (95% CI 1.12–3.48) after adjust-
ment for other cardiovascular confounding risk factors 
(Yaggi et al 2005).
OSA is observed in up to 62%–77% of patients acutely 
following a stroke (Dyken et al 1996; Bassetti and Aldrich 
1999; Parra et al 2000) although causality (in either 
direction) has not been proven. The presence of OSA has 
also been reported as an independent factor associated 
with increased mortality following ﬁ  rst ever stroke or 
transient ischaemic attack (Parra et al 2004). Further 
prospective studies (including further longitudinal data 
from the current large population-based epidemiological 
studies) are required to clarify the association between 
sleep-disordered breathing and stroke without the use of 
composite end-points.
Mechanisms
There are a number of possible mechanisms for the 
relationship between OSA and cardiovascular disease. 
Hypertension, independently associated with OSA, certainly 
will increase rates of cardiovascular disease. There is also 
evidence of increased sympathetic nervous system activity 
in subjects with OSA (Carlson et al 1993) and that at least 
daytime sympathetic nervous activity is correlated with 
the severity of OSA (Ziegler et al 2001). Treatment with 
CPAP reduces the increased sympathetic activity (Ziegler 
et al 2001; Heitmann et al 2004), suggesting a causal rela-
tionship. There is some evidence for a primary endothelial 
dysfunction. Kato et al (2000) have demonstrated impaired 
endothelial function in subjects with OSA who had blunted 
vasodilatation in response to acetylcholine. Ip et al (2004) 
also demonstrated impaired endothelium-dependent vaso-
dilatation in subjects which OSA and showed improve-
ment following treatment with CPAP. Nitric oxide has 
been implicated in the pathogenesis of vascular disease in 
OSA. Circulating nitric oxide levels, which have potent 
effects on endothelial relaxation, have been reported to be 
suppressed in OSA subjects (Ip et al 2000) and increase 
with treatment.
There are also a number of inflammatory changes 
seen in OSA which may contribute to atherosclerosis and 
vascular remodeling. OSA is associated with increased 
reactive oxygen species production in some leukocyte 
populations and increased adhesion molecules expression 
and increased monocyte adherence to human endothelial 
cells in vitro with reductions by treatment with CPAP 
(Dyugovskaya et al 2002; El-Solh et al 2002). Tumor 
necrosis factor-alpha (TNF-α), involved in the patho-
genesis of atherosclerosis, is also elevated in patients 
with moderate to severe OSA and falls with treatment 
with CPAP, suggesting a causal relationship (Minoguchi 
et al 2004). Riha et al (2005b) have recently demon-
strated that OSA is associated with the TNF-α-308A 
gene polymorphism, suggesting that the increased TNF-α 
production associated with this allele may be involved in 
the pathogenesis of OSA. This hypothesis is supported 
by the significant improvement in objective sleepiness 
and the small but significant improvement seen in AHI 
following treatment with etanercept, a TNF-α antagonist, 
compared with placebo (44.3 ± 10.3 vs 52.8 ± 9.1 com-
pared with a baseline of 55.9 ± 11.6 events per sleep hour) 
(Vgontzaz et al 2004). Patients with OSA may also have 
heightened coagulability, although the studies have not 
used well matched control populations. Robinson et al 
(2004) have demonstrated increased plasma levels of 
activated coagulation factors XIIa (a marker of endo-
thelial activation or dysfunction) and VIIa, thrombin-
antithrombin complex (a marker of thrombin turnover) 
and soluble P-selectin in subjects with OSA compared 
with unmatched controls, although the levels did not fall 
following one month of therapeutic CPAP suggesting that 
confounding factors such as obesity may be involved. 
Patients with OSA compared with those without have 
been shown to have increased morning fibrinogen levels 
and blood viscosity in a recent cohort study of patients 
undergoing polysomnography (Steiner et al 2005). 
D-dimer, a degradation product of fibrin, is elevated in 
OSA indicating increased fibrinolytic activity with higher 
levels seen in patients with greater hypoxia (Shitrit et al 
2005). CRP, known to be a risk factor for cardiovascular 
events, is elevated in patients with OSA but does not fall 
with treatment, again suggesting the relationship is due 
to the confounding association with obesity rather than 
OSA per se (Guilleminault et al 2004).Neuropsychiatric Disease and Treatment 2006:2(3) 313
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Association with impaired glucose 
homeostasis
There is increasing evidence supporting a causal relation-
ship between OSA and metabolic syndrome, including 
hypertension, insulin resistance, impaired glucose toler-
ance, and dyslipidemia, which are signiﬁ  cant cardiac risk 
factors. OSA appears independently associated with insulin 
resistance and dyslipidemia (Ip et al 2002; Coughlin et al 
2004; Pujabi et al 2004) even after correction for obesity. 
Cross-sectional data from the Wisconsin Sleep Cohort 
Study (1387 participants) has shown a greater prevalence 
of diabetes with increasing severity of OSA (Reichmuth 
et al 2005). The OR (corrected for gender, age and body 
habitus) for a physician diagnosis of diabetes in subjects 
with an AHI of 15 or greater compared with less than 5 
was 2.30 (95% CI 1.28–4.11). Longitudinal data from 
the same study did not demonstrate a signiﬁ  cant relation-
ship with an OR for developing diabetes within a 4-year 
period with an AHI of 15 or more compared with less than 
5 was 1.62 (95% CI 0.67–3.65). CPAP has been shown 
to improve insulin resistance within two days of treat-
ment with CPAP (Harsch et al 2004). Multiple studies 
have demonstrated improvements in glucose levels and 
signiﬁ  cant falls in hemoglobin A1C in subjects with Type 
2 diabetes and OSA treated with CPAP (Babu et al 2005; 
Hassaballa et al 2005). There may also be a dose-response 
relationship between the improvement in hemoglobin A1C 
and CPAP usage (Babu et al 2005). These data support a 
causal relationship between the sleep-disordered breath-
ing and impaired glucose homeostasis and indeed presents 
glucose dysregulation as another potential indication for 
the treatment of OSA with CPAP.
Thus, OSA is a highly prevalent condition which is likely 
to increase in prevalence associated with the epidemic of 
obesity in Western societies and is associated with signiﬁ  -
cant sequelae. As such, OSA presents a substantial burden 
of disease and a major public health issue. However, large 
population-based epidemiological studies demonstrate that at 
least 80% of all subjects with moderate to severe OSA remain 
undiagnosed and untreated, particularly women (Young et al 
1997b; Kapur et al 2002).
Treatment
Conservative treatment
Patients with OSAS are frequently advised to avoid supine 
sleep, minimize alcohol intake, and reduce weight. Most 
studies report that moderate alcohol consumption increases 
respiratory disturbance and heart rate during sleep in both 
non-snoring (Hertzog and Riemann 2004) and snoring men 
(Scanlon et al 2000; Hertzog and Riemann 2004) but some 
studies have not demonstrated exacerbation of OSA by 
alcohol (Teschler et al 1996). There have been no systematic 
reviews of the effectiveness of the advice to reduce alcohol 
intake but the data from studies assessing the impact of addi-
tional alcohol on sleep-disordered breathing would suggest 
that this advice is appropriate.
Avoidance of supine sleep can be achieved using a 
number of inexpensive devices such as a backpack containing 
a soft ball. This treatment can be effective in reducing time 
spent supine (Jokic et al 1999) and can improve AHI in 
positional OSA (Cartwright et al 1985, 1991) although 
less effectively than with CPAP (Jokic et al 1999). This 
treatment has been shown to have similar effects to CPAP 
in positional OSA to improve sleep architecture, subjective 
sleepiness, ability to maintain wakefulness during the day, 
psychometric test performance, mood scales, and quality of 
life measures in a single prospective cross-over study (Jokic 
et al 1999). In contrast, modifying posture using a shoulder-
head elevation pillow was signiﬁ  cantly less effective than 
CPAP in one small study of subjects with variable-severity 
OSA, although 2/14 subjects did normalize AHI with this 
therapy, including one subject with underlying severe OSA 
(Skinner et al 2004).
Few studies have evaluated the effect of major weight 
loss on the severity of OSA. Dixon et al investigated the 
effect of laparoscopic gastric banding on severely obese 
subjects with severe OSA (Dixon et al 2005). Weight loss 
of 44.9 ± 22 kg resulted in a signiﬁ  cant fall in AHI from 
61.6 ± 34 to 13.4 ± 13 and improvement in sleep architecture 
and subjective sleepiness. Longitudinal data of 690 subjects 
from the Wisconsin Sleep Cohort Study (Peppard et al 
2000a) demonstrated that lesser weight loss will also 
inﬂ  uence severity of OSA, with a 10% weight loss associated 
with a 26% (95% CI 18%–34%) fall in AHI. Conversely, 
a 10% weight gain resulted in a 32% (20%–45%) increase 
in the AHI.
Continuous positive airway 
pressure (CPAP)
CPAP, ﬁ  rst described in 1981, remains the mainstay of 
treatment in this condition (Sullivan et al 1981). The 
treatment consists of a ﬂ  ow generator attached by tubing 
to a nasal or oronasal mask from which the air is vented 
(Figure 2). The resistance of air ﬂ  ow across the vent leads 
to the generation of positive pressure in the mask which is Neuropsychiatric Disease and Treatment 2006:2(3) 314
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transferred to the upper airway. Positive airway pressure 
in the pharyngeal lumen overcomes the tendency of the 
airway to collapse with the loss of dilator muscle activity 
at sleep onset, therefore acting as a pneumatic splint. The 
treatment itself is conceptually simple; however, consider-
able effort on the part of the patient is required to wear the 
therapy each night.
Optimal CPAP settings must be individually determined. 
Conventionally, patients require labor-intensive laboratory 
based CPAP titration polysomnography. CPAP settings are 
adjusted during the study to control apneas, hypopneas, ﬂ  ow 
limitation, oxygen saturation, and arousals. There are no 
agreed standards on techniques of CPAP titration and it is 
likely there is considerable variability between laboratories. 
Furthermore, increased upper airway resistance may persist 
despite increases in CPAP settings to abolish features of air-
ﬂ  ow limitation (Monsterrat 1995). The demand for laboratory 
investigations greatly outstrips supply (National-Institutes-
of-Health-Report 1994) leading to log waiting times for 
polysomnography in many services.
The lack of standardization of CPAP titration and the 
resource-intense nature of laboratory CPAP titration has 
led to alternative techniques to determine optimal CPAP 
settings. Fitzpatrick et al (2003) suggested that patients could 
effectively self-titrate CPAP without laboratory-titration 
based on the comfort and response to the treatment. Hukins 
(2005) demonstrated that the use of arbitrary-pressure CPAP 
according to body mass index resulted in similar subjective 
sleepiness, adherence to CPAP and quality of life measures 
to laboratory-determined CPAP pressure. However, the 
commonest technique used as an alternative to laboratory poly-
somnography is auto-titrating positive airway pressure (APAP). 
APAP devices use algorithms to estimate upper airway 
resistance and automatically adjust the delivered airway 
pressure without the need for an attending technician. The 
principles of this treatment are discussed below. These 
devices are capable of storing data including pressures 
delivered (usually mean or median pressure, maximal pres-
sure and the 95th percentile pressure or the pressure limit 
that is exceeded for only 5% of the study time), system 
leaks (mask and/or mouth leaks), and an estimation of the 
frequency of persistent respiratory events. Some devices 
also allow for integration of oximetry data to the other 
stored data. The physician can then review the data stored 
by the APAP device to decide optimal CPAP settings. The 
pressure recommended by APAP devices correlates well 
to laboratory-determined pressures (Stradling et al 1997; 
Teschler et al 1997) but there is evidence that different 
devices using different algorithms and technology can 
recommend quite different settings. Kessler et al (2003) 
found considerable differences in the 95th percentile 
pressure between a device adjusting settings according to 
measurements of airﬂ  ow compared with a device using 
the forced-oscillation technique to estimate upper airway 
impedance, with a mean difference of 2.9 cm H2O between 
the devices. The other area of concern with the use of this 
technology is the potential effect on long-term compliance 
which may arise by transferring patient contact from the 
laboratory to the home. Means et al (2004) reported that 
patients who underwent home CPAP titration had lower 
nightly CPAP usage than those who underwent laboratory 
titration (3.9 vs 5.0 hours per night). The authors hypoth-
esized that the loss of support and education provided by 
sleep technologists may explain this ﬁ  nding.
A 1997 systematic review of the health consequences of 
OSA and effectiveness of CPAP concluded that the pubic 
health risk of OSA was exaggerated and was highly critical of 
the paucity of high quality evidence supporting this therapy 
(Wright et al 1997). This condemning review stimulated 
numerous randomized–controlled trials to document the 
efﬁ  cacy of CPAP in this condition.
Effect of CPAP on sleep architecture
There is randomized–controlled evidence that CPAP 
improves sleep parameters in subjects with OSA. McArdle 
and Douglas (2001) reported that CPAP resulted in a signiﬁ  -
cant improvement in arousals during sleep and redistribu-
tion of Stage 1 sleep to deeper Stage 3/4 (slow wave) sleep 
compared with oral placebo. The change in the frequency of 
arousals during sleep and increased proportion of slow wave 
Figure 2 Subject demonstrating the principle of nasal CPAP. The ﬂ  ow generator 
(a) delivers air through a smooth tube (b) to the mask (c) from which the air is vented 
(d) generating pressure in the mask which is transmitted to the upper airway.Neuropsychiatric Disease and Treatment 2006:2(3) 315
Obstructive sleep apnea
sleep correlated to improvements in subjective sleepiness. 
An earlier study by Loredo et al (1999) comparing the effects 
of therapeutic with sham CPAP also showed a reduction 
in arousals during sleep, improved oxygen saturation and 
reduced respiratory disturbance but the sleep stage propor-
tions did not differ.
Effect of CPAP on daytime function
A Cochrane collaboration review (White et al 2001) 
concluded that CPAP resulted in significant improve-
ments in objective and subjective sleepiness and several 
quality of life and depression measures relative to pla-
cebo. The placebo used in the randomized-controlled 
studies takes the form of either oral placebo tablets 
(Engleman et al 1998, 1999; Barbe et al 2001; Barnes et al 
2002, 2004) or sham CPAP (CPAP at ineffective pressure) 
(Loredo et al 1999; Montserrat et al 2001). There has been 
considerable debate about which is the better placebo. 
CPAP significantly improves both objective sleepiness 
(Engleman et al 1998) measured by the Multiple Sleep 
Latency Test and subjective sleepiness (Engleman et al 
1998; Montserrat et al 2001) assessed by the Epworth 
Sleepiness Score (Johns 1991), a self-reported scale 
based on patient’s tendency to doze during 8 different 
passive activities. Some quality of life measures improve 
with CPAP relative to placebo. The disease-specific 
Functional Outcomes Sleep Questionnaire (Weaver et al 
1997b) showed improved social function, activity level, 
and vigilance with 6 weeks of CPAP therapy relative 
to placebo in 45 patients with severe OSA (Montserrat 
et al 2001). A number of studies have shown improve-
ments both in the short term (Montserrat et al 2001; 
Parish and Lyng 2003; Kawahara et al 2005) and after 
up to 18 months (Sin et al 2002a; Pichel et al 2004) of 
CPAP therapy in some of the sub-scales of the generic 
SF-36 quality of life questionnaire. The Vitality scale 
may show the largest effect size with CPAP therapy (Sin 
et al 2002a; Pichel et al 2004). Patients with more severe 
OSA appear to show the greatest improvements in quality 
of life with CPAP (Sin et al 2002a). Improvements are 
not only seen in the patient. An interesting finding from 
Parish et al (2003) was that there is improvement in the 
quality of life of the bed partners of patients with OSA 
after treatment with CPAP.
A randomized–controlled study of 45 subjects with 
severe OSA demonstrated that short-term CPAP therapy 
improved some but not all neuropsychological assessments 
(namely Digit Span Test Forward and Backward, Complex 
Figure Recall, SteerClear, and Digit Symbol tests – refer 
to original paper for details) relative to placebo (Henke 
et al 2001). Other studies have not shown improvements 
in neurocognitive function (Engleman et al 1993; Bardwell 
et al 2001; Monastero et al 2001; Barnes et al 2002), 
but many of these studies were conducted in mild OSA 
where baseline tests showed only minimal abnormality 
and therefore the effect size of CPAP is likely to be quite 
small. High intelligence may have some protective effect 
against the neurocognitive effects of OSA. Alchanatis et al 
(2005) demonstrated that patients of normal intelligence 
with OSA show deﬁ  cits in attention and alertness com-
pared with controls that reversed with prolonged CPAP 
treatment. These CPAP-responsive deﬁ  cits were not seen 
in highly intelligent patients, possibly reﬂ  ecting increased 
“cognitive reserve”.
In patients with mild to moderate OSA, CPAP was 
shown to be no more effective than placebo in improving 
subjective or objective sleepiness, quality of life measures 
or neurobehavioral function in a randomized–controlled 
trial of 28 subjects, although self-reported symptoms 
including snoring, restless sleep, and irritability did 
improve (Barnes et al 2002). Another randomized placebo-
controlled study of mild to moderate OSA by Engleman 
did show improvement in subjective sleepiness, some 
sub-scales of the generic SF-36 quality of life assessment 
and improvement in 2 of 7 cognitive tests but objective 
sleepiness did not improve (Engleman et al 1999). CPAP 
has been compared with a mandibular advancement splint 
(MAS) in mild OSA in several studies. CPAP is more effec-
tive in reducing AHI and arousals during sleep than the 
MAS (Ferguson et al 1996; Engleman et al 2002; Barnes 
et al 2004) but the effects on subjective sleepiness and 
quality of life are variable. Some studies have demonstrated 
patient preference for CPAP (Engleman et al 2002; Barnes 
et al 2004) and others for the dental appliance (Ferguson 
et al 1996).
Barbe et al (2001) explored the role of CPAP therapy 
in subjects with severe OSA but who were free of daytime 
sleepiness. Fifty-ﬁ  ve subjects with severe OSA were ran-
domized to either 6 weeks of effective CPAP or sham CPAP. 
There were no differences between the groups in subjective 
or objective sleepiness, quality of life, blood pressure or 
neurocognitive assessment in the short term. The authors 
concluded that CPAP is not indicated in non-sleepy patients 
with signiﬁ  cant OSA but long-term studies are required 
given the association between OSA and cardiovascular 
disease.Neuropsychiatric Disease and Treatment 2006:2(3) 316
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Effect of CPAP on cardiovascular risk factors
The evidence shows that CPAP improves sleep parameters, 
daytime symptoms, quality of life and possibly 
neuropsychological function. In view of the increasing 
evidence of an association between OSA and cardiovas-
cular disease, does CPAP reduce the risk of cardiovascular 
complications?
There have been methodological problems for many 
studies assessing the effect of CPAP on blood pressure, 
including selection of adequate controls. The effect of 
CPAP on blood pressure remains controversial. Short-
term, randomized studies have shown reduction in daytime 
blood pressure compared with placebo. Faccenda et al 
(2001) demonstrated a small fall in diastolic blood pres-
sure in 68 normotensive subjects with OSA treated with 
CPAP compared with oral placebo and a fall in systolic 
blood pressure only in the group with more frequent noc-
turnal desaturation. Pepperell et al demonstrated falls in 
both systolic and diastolic blood pressure with therapeutic 
CPAP compared with sham CPAP with a difference in 
mean blood pressure of 3.3 mmHg between the groups 
(Pepperell et al 2002). Becker et al (2003) showed much 
larger falls in diurnal and nocturnal blood pressure of 
about 10 mmHg (diastolic, systolic and mean) in patients 
with moderate to severe OSA treated with effective CPAP 
compared with a sub-therapeutic CPAP setting which 
reduced respiratory disturbance by only 50%. There is a 
suggestion that effects on blood pressure are greater with 
more severe OSA (Faccenda et al 2001; Pepperell et al 
2002). Other studies have shown no signiﬁ  cant difference 
between the effect CPAP and placebo on diurnal blood 
pressure (Engleman et al 1996; Dimsdale et al 2000), 
although one study did show improvement in daytime 
blood pressure with CPAP only in the sub-group of 
patients whose blood pressure did not fall during sleep 
(Engleman et al 1996). Several studies have shown a fall 
in nocturnal but not diurnal blood pressure (Dimsdale et al 
2000; Hla et al 2002).
CPAP leads to reductions in plasma norepinephrine 
levels by both increases in norepinephrine clearance and 
decreases in diurnal and nocturnal excretion compared 
with sham CPAP or oxygen supplementation alone 
(Mills et al 2006). Treatment of OSA with CPAP has 
also been shown to reduce daytime muscle sympathetic 
nerve activity in patients with heart failure (Usui et al 
2005). The improvement in sympathetic activity is one 
likely mechanism for the changes in blood pressure seen 
with CPAP.
There have been no randomized–controlled trials to 
assess the impact of CPAP on cardiovascular disease. 
Several cohort studies suggest that CPAP may reduce 
cardiovascular outcomes, although these are usually 
assessed as a composite outcome of several cardiovas-
cular events. Marin et al (2005) followed 1387 sleep 
clinic patients (including simple snorers, untreated mild–
moderate OSA, untreated severe OSA, and 372 treated 
OSA subjects) and 264 healthy controls over 10.1±1.6 
(SD) years and compared fatal cardiovascular events 
(death from myocardial infarction or stroke) and non-fatal 
cardiovascular events (non-fatal myocardial infarction, 
non-fatal stroke, or invasive coronary artery procedures). 
Patients with untreated severe OSA had significantly 
higher incidence of both fatal and non-fatal cardiovascular 
events than the other cohorts with no difference between 
the normal control and treated OSA cohorts. The study 
did report excellent follow-up rates but analysis was not 
intention to treat. Milleron et al (2004) prospectively 
assessed 54 patients with both OSA and coronary artery 
disease over a mean of 86.5 months and demonstrated that 
the cohort receiving treatment (21 with CPAP and 4 with 
upper airway surgery) had a significantly lower incidence 
of a composite endpoint of cardiovascular death, acute 
coronary syndrome, hospitalization for heart failure, or 
need for coronary revascularization. Doherty et al (2005) 
prospectively followed 107 subjects with OSA treated 
with CPAP compared with 61 subjects non-tolerant of 
CPAP over an average 7.5 years with a follow-up rate of 
75%. There was a significant difference in deaths from 
cardiovascular disease in the untreated cohort (14.8% 
compared with 1.9%) but there was no difference in the 
incidence of new cardiovascular events (hypertension, 
cardiac disorder or stroke).
Effect of CPAP on mortality
Campos-Rodriguez et al (2005) retrospectively reviewed the 
mortality of patients with OSA comparing those compliant 
with CPAP to those non-compliant. There was a dose-
response relationship between 5-year cumulative survival 
and CPAP adherence (comparing average nightly CPAP use 
of  1 hour, 1–6 hours and  6 hours). The major cause of 
death was related to cardiovascular disease.
CPAP adherence
The eternal challenge in sleep medicine is maximizing 
the adherence of patients to CPAP. Weaver et al (1997a) 
reported a bimodal distribution of use in the ﬁ  rst three Neuropsychiatric Disease and Treatment 2006:2(3) 317
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months of treatment with about half of the subjects using 
the therapy consistently (use on  90% of nights with an 
average usage of 6.22±1.21 hours/night) and the other 
half using therapy intermittently with an average use of 
only 3.45±1.94 hours/night on the nights the therapy was 
used. The authors could not identify factors predictive 
of usage pattern. Other studies have reported objective 
nightly use of CPAP for 4.5–5.8 hours/night (Kribbs et al 
1993; Rauscher et al 1993; Engleman et al 1994; Sin et al 
2002b; Drake et al 2003). Usage of CPAP is over-reported 
by patients compared with objective measurements based 
on the CPAP device’s in-built hour-meter (Rauscher et al 
1993). McArdle et al (1999) reviewed the adherence to 
CPAP in 1103 patients in up to 84 months of treatment 
with CPAP. Eighty-four per cent of subjects continued to 
use CPAP 12 months after commencing the therapy and 
the use of CPAP plateaued only after 4 years, with 68% 
continuing to adhere to therapy (Figure 3). The independent 
variables inﬂ  uencing continued use of CPAP were CPAP 
usage at 3 months (with a relative risk [RR] of stopping 
CPAP of 13.8 comparing  2 hours vs  2 hours), AHI 
(RR of 2.48 AHI   15 vs AHI   15), presence of subject 
sleepiness (RR of 1.92), and snoring status (RR of 2.76 
non-snorer vs snorer).
Auto-titrating positive airway 
pressure (APAP)
A number of APAP devices have been developed either for 
home use or for supervised or unsupervised CPAP titration. 
I will discuss here only the chromic treatment of OSA in 
the home with APAP. These devices automatically adjust 
delivered airway pressure according to algorithms to estimate 
upper airway resistance. These algorithms utilize different 
parameters including snoring, apnea, hypopnea, airﬂ  ow 
limitation, and impedance by the forced oscillation technique. 
The algorithms used vary between devices, and as a result the 
devices have different response characteristics (Kessler et al 
2003; Hussain et al 2004; Peveragie et al 2004; Stammnitz 
et al 2004). There are a number of theoretical beneﬁ  ts of 
APAP over conventional CPAP. APAP does not require 
laboratory pressure-determination polysomnography which 
may reduce the delay to initiation of treatment and health-
related costs (Planes et al 2003). As the delivered pressure 
varies according to “instantaneous” need, APAP may be 
preferable in subjects who have great variations in pressure 
requirement, for example subjects with predominantly 
REM sleep or supine-related OSA. Furthermore, APAP 
may address longer-term changes in pressure requirement 
that may occur with changes in weight without the need for 
repeat polysomnography.
There have been a number of randomized–controlled 
trials evaluating APAP, although most of these have been 
short term (generally 2 months or less of APAP) and cross-
over studies. APAP appears to be equally effective as ﬁ  xed 
pressure CPAP in improving respiratory disturbance and 
sleep architecture (Ficker et al 1998; Konerman et al 1998; 
D’Ortho et al 2000; Randerath et al 2001). APAP has been 
consistently shown to deliver lower average airway pressures 
relative to conventional ﬁ  xed-pressure CPAP (Konerman 
et al 1998; D’Ortho et al 2000; Hudgel and Fung 2000; 
Teschler et al 2000; Randerath et al 2001; Massie et al 
2003; Hukins 2004), with APAP delivering a lower mean 
pressure of 0.9–4.2 cm H2O. Some studies have also shown 
fewer leaks (mask and/or mouth) recorded by the device 
(Teschler et al 2000; Hukins 2004) as a direct consequence 
of lower airway pressures. Most studies have not demon-
strated improved compliance with APAP compared with 
ﬁ  xed-pressure CPAP (D’Ortho et al 2000; Hudgel et al 
2000; Teschler et al 2000; Randerath et al 2001; Hukins 
2004) but some studies have shown increased proportion 
of nights used (Konerman et al 1998) or longer use of 
APAP on the nights patients used treatment (Hudgel et al 
2000). Massie et al (2003) reported higher average nightly 
use by a mean of 35 minutes in patients using APAP. One 
study (Hukins 2004) reported improved compliance with 
APAP in patients who had complained of any side-effect 
with CPAP, including pressure intolerance, bloating, or 
leaks, but this was based only on post hoc analysis and 
on small numbers. The one study comparing APAP with 
Figure 3 Proportion of patients continuing CPAP over time. The proportion adhering 
to CPAP continues to fall over the ﬁ  rst 4 years of therapy. Reprinted from McArdle N, 
Devereux G, Heinarnejad H, et al. 1999. Long-term use of CPAP therapy for sleep 
apnea/hypopnea syndrome.  Am J Respir Crit Care Med, 159:1108-14. Copyright © 1999, 
with permission from American Thoracic Society.
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ﬁ  xed-pressure CPAP speciﬁ  cally in subjects with high 
within-night variability in pressure requirement (related to 
sleep position, sleep stages, or other factors such as alcohol) 
did not show improved compliance, although subjective 
sleepiness assessed by the Epworth Sleepiness Score was 
signiﬁ  cantly lower statistically but not clinically with APAP 
(Noseda et al 2004). Other studies have not shown differ-
ences in subjective sleepiness (Ficker et al 1998; D’Ortho 
et al 2000; Hudgel et al 2000; Teschler et al 2000; Massie 
et al 2003; Planes et al 2003; Hukins 2004). The other poten-
tial beneﬁ  t of APAP devices is the ability to record data on 
technical factors such as leaks and persistent respiratory 
disturbance, although the impact of these data has not been 
systematically assessed.
Based on current knowledge, it can be said that APAP 
seems comparable to ﬁ  xed-pressure CPAP. There are poten-
tial beneﬁ  ts in avoiding laboratory sleep studies but further 
research is required to determine the role of APAP in the 
management of OSA.
Mandibular advancement splints (MAS)
Mandibular advancement splints or MAS (also referred to 
as mandibular advancement devices [MAD] or mandibular 
repositioning devices in the literature) are the main alternative 
treatment to CPAP in the management of OSA. These dental 
devices are worn during sleep to advance the mandible 
(Figure 4). Not all subjects are suitable for this type of 
therapy. Oral appliances cannot be used in those who are 
edentulous, have inadequate mouth opening, a strong gag, 
or temporo-mandibular joint (TMJ) instability (such as TMJ 
clicking). The devices have been shown to increase oropha-
ryngeal dimensions in wakefulness, particularly increasing 
the lateral diameter of the velopharynx (Ryan et al 1999; 
Kyung et al 2005) and reducing the curvature of the anterior 
velopharyngeal wall (corresponding to the posterior border of 
the soft palate) (Tsuiki et al 2004). MAS have been shown to 
reduce upper airway collapsibility in sleeping subjects with 
OSA (Ng et al 2003).
The efﬁ  cacy of oral appliances in OSA has been assessed 
in many randomized–controlled trials. A systematic review 
of the evidence for the efﬁ  cacy of these devices has been 
performed by the Cochrane Collaboration (Lim et al 2004). 
MAS therapy improves subjective sleepiness and improves 
AHI relative to controls but is less effective than CPAP in 
reducing AHI. Subjective sleepiness improves in 82%–96% 
of subjects with moderate–severe OSA (Mehta et al 2001; 
Gotsopoulos et al 2002) but objective sleepiness based on 
mean sleep latency during a Multiple Sleep Latency Test 
does not differ from controls (Gotsopoulos et al 2002). 
Most studies have not shown a difference between CPAP 
and MAS therapy in subjective sleepiness (Tan et al 2002; 
Barnes et al 2004) although CPAP is more effective in 
reducing AHI (Ferguson et al 1997; Barnes et al 2004). MAS 
therapy has been compared with uvulopalatopharygoplasty 
(UPPP) in several randomized–controlled studies. MAS 
are superior in improving polysomnographic parameters in 
a randomized cohort assessed at 1 year (Walker-Engstrom 
et al 2000) and 4 years (Walker-Engstrom et al 2002) of 
treatment.
The greatest limitation to the use of dental appliances 
in OSA is the unpredictable response to therapy. Complete 
responses in OSA (deﬁ  ned as an AHI less than 5–10 and 
control of symptoms) with dental appliances are reported in 
only 34%–63% of subjects (Ferguson et al 1997; Walker-
Engstrom et al 2002; Gotsopoulos et al 2004; Marklund et al 
2004) with at least partial responses (deﬁ  ned as a  50% 
reduction in AHI) seen in 60%–81% (Ferguson et al 1997; 
Walker-Engstrom et al 2002; Gotsopoulos et al 2004). 
Figure 4 Mandibular advancement splints showing both adjustable appliance (a) which uses a hinge to adjust mandibular advancement or one-piece mono-block appliance 
(b) with ﬁ  xed mandibular advancement.
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Selection of patients for MAS therapy is controversial but 
critical given the variable response rates to this therapy. 
There are no uniform predictors of success in the literature 
but some authors have reported increased success in mild 
OSA or habitual snoring (Mehta et al 2001; Marklund et al 
2004), supine-exacerbated OSA in men (Marklund et al 
2004), lower neck circumference, and some cephalometric 
measurements (Mehta et al 2001). Most studies found no 
predictors of success with MAS.
Mild side-effects with the dental appliances are seen in 
up to 86% of subjects, including mucosal drying, hyper-
salivation, temporo-mandibular joint, myo-facial, or tooth 
discomfort (Pantin et al 1999; Fritsch et al 2001). The most 
serious side-effect of oral appliances is malocclusion, which 
may occur in up to 14% of subjects and is poorly perceived 
by the patient (Pantin et al 1999). Studies of long-term com-
pliance of this therapy are limited by the lack of objective 
measures and the dependence on patient self-reports. Studies 
show long-term continuation rates with this therapy in the 
order of 62%–76% (Pantin et al 1999; Walker-Engstrom et al 
2002; Marklund et al 2004).
MAS therapy can be an effective treatment for OSA but it 
has lower efﬁ  cacy in improving polysomnographic variables 
and has lower response rates than CPAP. At this time, the 
treatment is regarded as second-line therapy in patients 
intolerant of CPAP or perhaps ﬁ  rst-line in habitual snorers 
or minimally symptomatic mild OSA. Further research 
is required to direct optimal selection of patients who would 
beneﬁ  t from this therapy.
Surgical treatment of OSA
Surgical intervention by tracheostomy was the ﬁ  rst effect 
treatment of OSA but the role of surgery in this condition 
has greatly diminished with the development of more 
acceptable or effective treatments, in particular CPAP. 
Although patients are attracted by the option of curative 
therapy, there is a paucity of high quality evidence for the 
use of surgery in OSA. The major surgical interest is in 
palatal surgery, either uvulopalatopharyngoplasty (UPPP) 
or laser-assisted uvuloplasty (LAUP). This review will 
not consider the role of tonsillectomy in individuals with 
tonsillar enlargement.
Palatal surgery
A Cochrane Collaboration systematic review of this therapy 
did not support the widespread use of surgical treatment for 
unselected patients with OSA (Sundaram et al 2005). Several 
studies have explored the role of LAUP in the treatment of 
OSA. Ferguson et al (2003) randomized 45 subjects with 
mild OSA to LAUP or no treatment (control) and reported 
only a small improvement in AHI in the treatment group 
(from 18.6 ± 4.3 to 14.7 ± 7.5) (Ferguson et al 2003). Only 
17% of subjects achieved a near normal AHI of  10 with 
treatment but 48% reported a subjective improvement in 
snoring. Larrosa et al (2004) compared 28 patients with 
snoring and mild to moderate OSA randomized to either 
LAUP or to a surgical placebo involving the injection 
of saline to the base of the uvula under local anesthesia 
followed by a weekly oral placebo for 12 weeks (Larrosa 
et al 2004). There were no differences in the AHI or the 
Epworth Sleepiness Scale (subjective sleepiness) between 
groups or from baseline when evaluated after 3 months.
There are serious methodological problems in the 
large number of observational studies in the literature, 
including small sample size with low study power, lack 
of control groups, selection bias, incomplete follow-up, 
and poor selection of end-points (for example deﬁ  ning 
success as only AHI   20 and at least a 50% reduction 
in AHI, which as best represents partial response) (Pepin 
et al 1996). Sher et al (1996) performed a meta-analysis 
of surgical interventions for OSA and reported a success 
rate of 41%, deﬁ  ned as a 50% fall in AHI to an AHI   20. 
This end-point represents partial response only and will 
overestimate the true success rate. Weighted mean results 
from 19 studies showed only UPPP resulted in only a 
38.2% fall in AHI from a baseline of 60.0. The addition 
of procedures such as surgical tongue base suspension 
to the UPPP procedure may improve treatment response 
rates but normalization of sleep disordered breathing is 
still unlikely (Omur et al 2005). Even the optimal surgical 
technique is not clear. Data are inconclusive whether the 
lower morbidity LAUP is equivalent to UPPP because of 
methodological ﬂ  aws (Littner et al 2001). The American 
Academy of Sleep Medicine published practice parameters 
on the use of LAUP in 2001 and concluded that LAUP is 
not recommended for treatment of sleep-related breathing 
disorders (Littner et al 2001).
Maxillofacial surgery
The Stanford University School of Medicine (Li et al 
1999a, 1999b) have proposed a step-wise surgical approach 
to OSA. Phase I surgery involves UPPP and genioglossus 
advancement with hyoid myotomy-suspension. Patients not 
responsive to this intervention proceed to Phase II treatment 
of maxillary-mandibular advancement osteotomy. Riley 
et al have reviewed 306 consecutively treated patients and Neuropsychiatric Disease and Treatment 2006:2(3) 320
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reported a fall in AHI from 55.8 ± 26.7 at baseline to 9.2 ± 7.5 
post-operatively (Riley et al 1993). However, there were 
major methodological problems including lack of a control 
group, potential for selection bias, and incomplete follow-
up. Reports from other centers, although promising, are 
also uncontrolled, non-randomized before and after studies 
(Conradt et al 1998; Lee et al 1999). Surgical expertise for 
this approach is available only in a few centers at this time. 
Randomized–controlled studies are required to validate the 
treatment.
Radiofrequency tissue volume reduction
Radiofrequency (RF) tissue volume reduction of the tongue 
was proposed as a potential intervention for OSA in 1997 
by Powell et al (1997) based on the results of an animal 
model. RF energy is delivered into the tongue by a needle 
electrode causing a localized thermal lesion that results in 
scarring and a 26% volume reduction at the treatment site. 
Observational studies have shown only a partial response 
in AHI to RF treatment (Li et al 2002; Stuck et al 2002). 
Woodson et al (2003) reported on the outcomes of RF 
tissue ablation applied to both the tongue base and palate in 
subjects with mild to moderate OSA and hypersomnolence. 
Subjects were randomized to active intervention with three 
RF lesions in each of the tongue and soft palate, sham-RF 
(where the electrodes were introduced into the tongue and 
soft palate but RF not delivered), or CPAP. The AHI was 
signiﬁ  cantly lower with CPAP than with RF treatment or 
placebo (4.6 vs 16.8 and 13.6 respectively). There were 
similar improvements in subjective sleepiness and the 
disease-speciﬁ  c Functional Outcomes of Sleep Quality 
of Life Questionnaire in both treatment arms. The lack of 
difference between RF volume reduction and CPAP may 
be explained by the suboptimal adherence with CPAP, 
averaging only 2.4 hours per night. This intervention at 
this time does not appear to be adequately effective as a 
management of OSA.
Hypoglossal nerve stimulation
As discussed, the loss of upper airway dilator muscle 
compensation for anatomically compromised airways at 
sleep onset appears important in the pathogenesis of OSA. 
Therefore, electrical stimulation of the dilator muscles 
during sleep may be a therapeutic option for this condi-
tion. Hypoglossal nerve stimulation in animal models has 
been show to increase pharyngeal airway size by ventral 
displacement of the ventral and lateral pharyngeal walls 
(Brennick et al 2004) and to reverse inspiratory flow 
limitation and snoring as effectively as CPAP (Bellemare 
et al 2005). In human studies, genioglossus muscle or 
hypoglossal nerve stimulation results in reduced upper 
airway collapsibility (the critical airway pressure at which 
obstruction occurs) and reduces airﬂ  ow limitation (Oliven 
et al 2003). Schwartz et al (2001) have also demonstrated 
improvement in sleep indices with unilateral hypoglossal 
nerve stimulation in 8 subjects with moderate to severe 
OSA (mean AHI improving in non-REM sleep from 
52.0 ± 20.4 to 22.6 ± 12.1 events per hour and in REM 
sleep from 48.2 ± 30.5 to 16.6 ± 17.1 per hour) (Schwartz 
et al 2001). Electrical nerve stimulation of upper airway 
dilator muscles has strong potential as a therapeutic option 
for OSA but at this time remains experimental.
Drug treatment of OSA
Just as a surgical cure, pharmaceutical treatment for OSA 
is an attractive option for the patient facing treatment with 
CPAP. A review by Smith et al (2001) did not support the 
use of a number of drugs compared with placebo, includ-
ing acetazolamide, protriptyline, medroxyprogesterone, 
clonidine, and aminophylline–theophylline.
In theory, the emerging knowledge on the neurochem-
istry of upper airway dilator muscle control would support 
a role for pharmacotherapy in the management of OSA. 
Serotoninergic agents particularly are an attractive phar-
macotherapy in theory in view of the excitatory effect of 
serotonin on hypoglossal motor neurons. Serotonin applied 
directly to the hypoglossal motor neuron in rats does 
signiﬁ  cantly increase tonic genioglossus activity (Jelev 
et al 2001) but does not abolish the phasic genioglossus 
excitation and suppression, indicating the roles for other 
transmitters. Serotonin does not cross the blood–brain 
barrier and therefore is not a suitable therapy for humans. 
Ritanserin, a serotonin 2A/2C receptor antagonist, has 
been shown to reduce pharyngeal critical pressure (the 
pharyngeal pressure at which upper airway collapse 
occurs which is a measure of airway collapsibility) in rats 
but has not been evaluated in human studies (Ogasa et al 
2004). Selective serotonin reuptake inhibitors (SSRI) have 
been investigated in human OSA. Paroxetine at doses of 
20–40 mg daily in short-term studies in small numbers 
of subjects with severe OSA does augment genioglos-
sus EMG activity but has little (Kraiczi et al 1999) to no 
(Berry et al 1999) effect on frequency of respiratory events 
during sleep.
Cross sectional data from the large Sleep Heart 
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Obstructive sleep apnea
a significantly lower prevalence of sleep-disordered 
breathing, defined as an AHI of  15 per sleep hour, in 
post-menopausal subjects using hormonal replacement 
therapy (HRT) with an OR adjusted for age, body mass 
index, and neck circumference of 0.55 (95% CI 0.41–0.75) 
(Shahar et al 2003). Interventional studies assessing the 
effect of HRT on OSA severity have involved only very 
small patient numbers (up to 21 subjects only). Not 
surprisingly, the outcomes have been inconsistent, with 
some studies showing no effect on AHI (Block et al 
1981; Cistulli et al 1994) and others demonstrating a 
reduction in respiratory events (Pickett et al 1989; Keefe 
et al 1999). More recent studies have been reported as 
“pilot studies” involving small numbers but have also 
shown reduction in respiratory disturbance during sleep. 
Manber et al (2003) reported a reduction in AHI from 
22.7 to 12.2 in just six post-menopausal subjects with 
estrogen monotherapy but no benefit from baseline with 
the combination of estrogen and progesterone. Wesstrom 
et al (2005) also reported an improvement in AHI (14.9 
improving to 3.6) in 5 subjects with mild OSA with 
treatment with estradiol and gestagen. Neither study 
included normal control subjects or placebo. There is a 
need for well designed, randomized–controlled studies 
to clarify the role of HRT in the management of OSA in 
poist-menopausal women.
The role of modafinil, a unique wakefulness-
promoting agent used in narcolepsy, in patients with 
OSA and residual sleepiness despite treatment with CPAP 
has been evaluated by several randomized–controlled 
trials. Early results were contradictory, some showing 
improvements in subjective and objective sleepiness 
with modafinil compared with placebo (Pack et al 2001) 
which continued in an open label extension of the study 
(Schwartz et al 2003), but another showed no benefit 
(Kingshot et al 2001). More recently, the benefits of 
modafinil therapy have been demonstrated by Black and 
Hirschkowitz (2005) who assessed 305 subjects with 
OSA and residual sleepiness on CPAP in a 12-week, 
double-blind, randomized, controlled trial comparing 
modafinil 200 mg or 400 mg daily and placebo. Subjec-
tive sleepiness improved with modafinil on the Epworth 
Sleepiness Scale by 4.5 points compared with a 1.8-point 
decrease with placebo. Objective sleepiness, assessed by 
mean sleep latency on the Maintenance of Wakefulness 
Test, improved in the modafinil groups (by 1.6 minutes 
for the 200-mg dose cohort and 1.5 minutes on the 
400-mg dose cohort) but deteriorated in the placebo group 
(shorter sleep latency by 1.1 minutes). Modafinil is now 
approved in the United States for treatment of residual 
sleepiness in patients with OSA treated with CPAP.
Golbart et al (2005) reported that the oral leukotriene 
receptor antagonist montelukast resulted in significant 
reductions in adenotonsillar size radiologically in children 
with mild OSA. There were statistically signiﬁ  cant improve-
ments in EEG arousals due to respiratory events, apnea 
index, and obstructive AHI compared with controls but the 
absolute improvements were only small and of question-
able clinical signiﬁ  cance. The effects of the montelukast 
would appear to be due to direct antagonism of the abun-
dant leukotriene receptors in adenoid tissue. These ﬁ  ndings 
are worthy of further evaluation by appropriately blinded, 
randomized–controlled studies.
Summary
Obstructive sleep apnea is a significant condition, both 
in terms of its prevalence and significant sequelae. There 
is increasing evidence of a causal relationship between 
OSA and cardiovascular and metabolic sequelae. CPAP 
remains the mainstay of treatment for this condition 
and has high-level evidence supporting its efficacy. 
However, the treatment is intrusive and not tolerated by 
all patients. There is evidence that dental appliances are 
effective in OSA but the difficulty is predicting those 
patients who may respond to this therapy. There is also 
evidence to support the recommendation of conservative 
interventions, particularly weight loss and avoidance of 
supine sleep in selected patients. The role of surgical 
interventions is not established in OSA but probably 
is not indicated in the majority of cases. Drug therapy 
plays little role.
The future direction in the management of OSA must 
address the poor patient acceptance of the current gold 
standard of treatment (CPAP). Auto-titrating CPAP will 
continue to evolve such that laboratory-based investiga-
tions will not be required for the majority of patients 
with OSAS. The role of dental appliances needs to be 
determined, with better predictive ability to select suit-
able candidates for this therapy. Research is striving for 
a cure to OSA. A curative therapy must address either 
the anatomical deficiencies of the upper airway utiliz-
ing techniques less highly specialized than the current 
maxillo-mandibular advancement procedures or must 
address the sleep-related loss of pharyngeal dilator 
muscle activity, pharmacologically, or by direct electrical 
stimulation.Neuropsychiatric Disease and Treatment 2006:2(3) 322
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